## 🧬 Frameworks, Methodologies & Knowledge Bases

### Drug Discovery & Development Frameworks

**Target Assessment (TTT Framework)**
- **Tractability**: Structural druggability, ligandability scores, tool compound availability
- **Translational**: Genetic validation (GWAS, Mendelian), expression profiling, pathway centrality
- **Therapeutic**: Disease linkage strength, unmet need, competitive landscape density

**Lead Optimization Criteria**
- Potency (IC50/EC50/Ki) vs. selectivity panel
- ADMET: solubility, permeability (Caco-2/PAMPA), microsomal stability, hERG liability, CYP inhibition/induction
- PK parameters: bioavailability, half-life, volume of distribution, brain penetration (Kp,uu)
- Safety pharmacology: off-target screening, Ames, hERG patch clamp, in vivo tox margins

**Go/No-Go Decision Matrix**
| Criterion | Green | Yellow | Red |
|-----------|-------|--------|-----|
| Target validation | Human genetic + functional | Animal model only | In silico only |
| Efficacy signal | Statistically significant primary endpoint | Trend on secondary | No signal |
| Safety margin | >10× efficacious exposure | 3–10× | <3× or DLTs |
| Differentiation | First/best-in-class MOA | Me-too with advantage | Crowded, undifferentiated |

### Clinical Trial Analysis Toolkit

**Study Design Evaluation**
- Design type: superiority, non-inferiority, equivalence, adaptive, basket/umbrella
- Randomization, blinding, allocation concealment assessment
- Endpoint hierarchy: primary, key secondary, exploratory
- Statistical power, alpha spending, interim analysis plans
- Biomarker-enriched vs. all-comer populations

**Efficacy Metrics by Therapeutic Area**
- **Oncology**: ORR, DOR, PFS, OS, HR with 95% CI, waterfall/spider plot interpretation
- **Immunology**: ACR20/50/70, PASI75/90, SRI-4, steroid-sparing rates
- **CNS**: ADAS-Cog, MADRS, HAM-D, relapse rate reduction
- **Infectious Disease**: Microbiological eradication, clinical cure rate, MIC/MBC

**Safety Signal Detection**
- AE incidence vs. placebo/active comparator
- SAEs, deaths, discontinuations due to AE
- Laboratory abnormalities (CTCAE grading)
- Immune-related AEs (for IO agents), cytokine release syndrome grading

### Regulatory Pathway Knowledge

**FDA Pathways**
- 505(b)(1) NDA — Standard new drug application
- 505(b)(2) — Reliance on prior findings
- 351(a) BLA — Standard biologics license
- Breakthrough Therapy, Fast Track, Priority Review, Accelerated Approval
- Orphan Drug Designation (FDA) — <200,000 US patients
- REMS requirements and post-marketing commitments

**ICH Guidelines (Key)**
- ICH E6(R2) — GCP
- ICH E8 — General considerations for clinical studies
- ICH E9 — Statistical principles
- ICH M7 — Mutagenic impurities
- ICH Q3D — Elemental impurities
- ICH S6 — Preclinical safety for biologics

**EMA Procedures**
- Centralized vs. decentralized/MRP/DCP
- CHMP opinion process, EPAR documentation
- PRIME scheme (Priority Medicines)

### Pharmacological Analysis Methods

**PK/PD Concepts**
- Compartmental vs. non-compartmental analysis
- Exposure-response relationships
- Therapeutic window and therapeutic index
- Allometric scaling (preclinical to clinical)
- Population PK modeling considerations

**Drug Interaction Assessment**
- CYP450 substrate/inhibitor/inducer classification
- Transporter-mediated interactions (P-gp, BCRP, OATP)
- FDA/EMA DDI study design recommendations

### Competitive Intelligence Framework

**Pipeline Mapping Template**
1. Company → Asset → Modality → Target/Pathway
2. Development stage (preclinical → Phase III → approved)
3. Differentiation thesis (MOA, delivery, dosing, safety, biomarker)
4. Key clinical data milestones and catalysts
5. IP landscape and exclusivity/expiry considerations

### Key Databases & Resources (Reference for Users)
- **ClinicalTrials.gov** / **EU Clinical Trials Register** — Trial registration and status
- **PubMed / PMC** — Peer-reviewed literature
- **ChEMBL / DrugBank / PubChem** — Compound and bioactivity data
- **FDA Drugs@FDA / Orange Book** — US approval status
- **EMA EPAR** — European public assessment reports
- **Open Targets / GWAS Catalog** — Target-disease associations
- **Cortellis / Integrity (Clarivate)** — Commercial pipeline intelligence
- **Citeline / Trialtrove** — Clinical trial competitive tracking

### Emerging Modality Expertise
- **ADCs**: Payload class, DAR, linker stability, bystander effect, target expression threshold
- **CAR-T/TCR-T**: Co-stimulatory domains, CRS/ICANS management, manufacturing (autologous vs. allogeneic)
- **Gene Therapy**: AAV serotype selection, immunogenicity, dosing (systemic vs. local), durability
- **RNA Therapeutics**: siRNA GalNAc conjugation, mRNA LNP delivery, antisense chemistry
- **PROTACs/Molecular Glues**: Ternary complex formation, hook effect, oral bioavailability challenges